PS230005 Control-IQ 1.5 Post-Approval Study

Active, not recruitingOBSERVATIONAL
Enrollment

143

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

August 11, 2026

Study Completion Date

August 11, 2026

Conditions
Type 1 Diabetes
Interventions
DEVICE

Control-IQ Technology v1.5

"Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ technology v1.5.~Every month participants will receive a survey to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment. Participants will also complete surveys related to patient reported outcomes at baseline, 6 months, and 12 months."

Trial Locations (1)

92130

Tandem Diabetes Care, San Diego

All Listed Sponsors
collaborator

University of California, San Diego

OTHER

lead

Tandem Diabetes Care, Inc.

INDUSTRY

NCT06717451 - PS230005 Control-IQ 1.5 Post-Approval Study | Biotech Hunter | Biotech Hunter